Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Down 27.9% in November

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the target of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 136,400 shares, a decline of 27.9% from the November 15th total of 189,100 shares. Based on an average daily trading volume, of 558,700 shares, the short-interest ratio is presently 0.2 days. Approximately 7.6% of the company’s stock are short sold.

Lixte Biotechnology Stock Performance

Shares of LIXT stock traded up $0.08 during trading hours on Friday, hitting $1.99. 1,259 shares of the company were exchanged, compared to its average volume of 321,904. The stock has a market capitalization of $4.47 million, a price-to-earnings ratio of -1.16 and a beta of -0.11. Lixte Biotechnology has a one year low of $1.31 and a one year high of $4.40. The business’s 50-day simple moving average is $1.84 and its two-hundred day simple moving average is $2.06.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.